Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 64Breast Neoplasms 20Kidney Neoplasms 19Gastrointestinal Stromal Tumors 16Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 9Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Colorectal Neoplasms 6Neuroendocrine Tumors 5Carcinoma, Hepatocellular 5Carcinoma 5Thyroid Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Sarcoma 3Pancreatic Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Kidney Diseases 3Glioblastoma 3Esophageal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Astrocytoma 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3

Interventions

Sunitinib 3avelumab 2Nutrition Assessment 2Axitinib 2spartalizumab 1pembrolizumab 1etelcalcetide hydrochloride 1aldesleukin 1Sorafenib 1Resistance Training 1Plasma Exchange 1Interleukin-2 1Adalimumab 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Kidney Diseases × Sunitinib × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT02684006 2025-07-30

JAVELIN Renal 101

Pfizer

Phase 3 Completed
886 enrolled 37 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT00460798 2010-11-16

SUNIKA

Pfizer

Completed
356 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡